BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
HCS-Pharma is pleased to launch BIOMIMESYS® Liver and Oncology in ready-to-use 384-well plate format for screening applications. Adopt BIOMIMESYS® 3D cell culture systems and obtain more predictive in vitro models. You can find our presentations Read more…
Soria et al. has published this year an interesting study about the modification leading by synucleopathy on the nanoscale organization and diffusivity of the extracellular space, through hyaluronan remodeling. Indeed the extracellular space (ECS), composed Read more…
HCS Pharma is pleased to present the whole range of BIOMIMESYS® Products. All our scientific team is ready to support you in using our 3D organ/tissue-specific cell-culture technology. Rediscover your cells in real in vitro Read more…
Parkinson’s disease affects more than 6 million people worldwide. This neurodegenerative disease is characterized by the death of dopaminergic neurons in the substantia nigra pars compacta, with intracellular accumulation of alpha-synuclein aggregates known as Lewi Read more…
In 2018, the World Health Organization announced 9.6 million deaths due to cancer, worldwide. Concerning the cancer cost, it was estimated to be more than US$ 1.16 trillion. For these reasons, developing more effective anti-cancer Read more…
As you may know, HCS Pharma makes use of Fluorescence Microscopy to perform biological assays and to test customers’ compounds. We often have questions about this technology, whether it is different or not from optical Read more…
Kaur et al. published in 2018 an interesting article about the effect of extracellular matrix (ECM) on skin cancer and immunity: “Remodeling of the collagen matrix in aging skin promotes melanoma metastasis and affects immune Read more…
On the occasion of the breast cancer awareness month, HCS Pharma is willing to thank all researchers working in the field to better understand the pathophysiology of disease, with the objective to find more efficient Read more…
Vaihere Cheung obtained her technology A-level (STL) in 2018 at La Mennais, in French Polynesia. Then she came to metropolitan France to reach a technician diploma in Biological engineering, specialized in biological and biochemical analysis, Read more…
At the occasion of the Breast Cancer Awareness Month, we would like to highlight the role of the interplay between the extracellular environment and the Cancer-Associated Fibroblasts (CAFs) on the tumoral development, including breast cancers. Read more…
There are 90% of failure in clinical trials, mainly due to safety and efficiency issues. In particular, the central nervous system is involved in 34% of failure in clinical trials, but only in 7% of Read more…
It’s pleasure to welcome Thomas in our team. After a four-month internship at the CrCHUM (Centre de recherche du Centre Hospitalier de l’Université de Montréal, Canada) in the field of microfluidic personalized medicine for prostate Read more…
Cells and the extracellular matrix (ECM): what is the relationship between them? This is a fundamental question. We hear many reflections about this question. Should we let cells work alone, or should we force cells Read more…
We are really proud to work on a real partnership with the team of Tokyo Future Style (TFS) Taïwan for almost a year now. Joseph Chou, member of our business advisory board and Pr John Read more…
This summer, Vitali et al. published an article in the Open Access Journal Cancers in which they assessed anticancer combination to treat neuroendocrine tumors (NETs) using in vitro models (2D + 3D cultures in BIOMIMESYS Read more…
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.